White Paper Reveals Design Process for babyLance Heelstick's Ease of Activation
Input from Neonatal Nurses Carefully Integrated Into Design Specifications for New Infant Heelstick Device
Atlanta, GA, October 05, 2012 --(PR.com)-- MediPurpose(tm), a master distributor and manufacturer of medical devices, today announced the publication of its latest white paper, “Reinventing a Better babyLance(tm) Infant Heel Incision Device: Translating User Requirements Into Design Specifications-Optimizing Ease-of-Activation.”
Launched in August, MediPurpose's all-new babyLance is a fully redesigned iteration of its original safe, easy and effective heelstick device. Among other features, the new heelstick was designed to meet end-user requirements for a heelstick incision device that was easy to activate.
The white paper describes how MediPurpose developed and implemented processes that accurately translated neonatal nurses' preferences into design specifications that drove the redesign of its new heelstick device.
"End-users of infant heelstick devices are neither product designers nor engineers -- and thus, they cannot be expected to provide the exacting design details that satisfy their subjective preferences for an ideal device," said MediPurpose founder and CEO Patrick Yi, who led the babyLance design team. "However, their clinical experience makes them very knowledgeable about what they like and don't like about a device."
The white paper is the latest in a series of publications that illustrate MediPurpose's intensive research and testing for its new neonatal heel incision device, including white papers on an overview of its research on neonatal heelstick user preferences, heelstick cut profiles for babyLance and leading competitors, a heelstick trigger activation survey at the 2011 NANN convention, and a simulated use study of pre-production units.
"MediPurpose certainly did not invent the infant heelstick-a medical device that has been around for several years," said Yi. "However, the market has expressed the need for a neonatal heelstick that better satisfies its end-users' unique requirements. By listening carefully to the end-users, we are confident that our new babyLance will meet their requirements."
About babyLance Infant Heel Incision Devices
Used by neonatal caregivers to collect blood samples from infants, the new babyLance features an ergonomic design to provide a secure and stable grip.
Combined with a redesigned trigger mechanism, the heelstick device is easy to activate, helping to deliver a consistent incision without damaging the baby's tender nerve fibers.
babyLance heelstick devices are available in two models:
* The babyLance BLP (Preemie), which delivers an incision depth of 0.85 mm.
* The babyLance BLN (Newborn), which delivers an incision depth of 1.00 mm.
To download the white papers, please visit http://www.medipurpose.com/downloads.
For more information about babyLance -- including pricing and no-cost product sample requests -- please visit http://www.medipurpose.com/babylance.
About MediPurpose
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance(tm) heel incision device, SurgiLance(tm) safety lancet and MediPlus(tm) advanced wound care products, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and distributors.
MediPurpose's Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose's medical products and solutions for inventors, innovators, manufacturers and distributors, please visit http://www.medipurpose.com.
Launched in August, MediPurpose's all-new babyLance is a fully redesigned iteration of its original safe, easy and effective heelstick device. Among other features, the new heelstick was designed to meet end-user requirements for a heelstick incision device that was easy to activate.
The white paper describes how MediPurpose developed and implemented processes that accurately translated neonatal nurses' preferences into design specifications that drove the redesign of its new heelstick device.
"End-users of infant heelstick devices are neither product designers nor engineers -- and thus, they cannot be expected to provide the exacting design details that satisfy their subjective preferences for an ideal device," said MediPurpose founder and CEO Patrick Yi, who led the babyLance design team. "However, their clinical experience makes them very knowledgeable about what they like and don't like about a device."
The white paper is the latest in a series of publications that illustrate MediPurpose's intensive research and testing for its new neonatal heel incision device, including white papers on an overview of its research on neonatal heelstick user preferences, heelstick cut profiles for babyLance and leading competitors, a heelstick trigger activation survey at the 2011 NANN convention, and a simulated use study of pre-production units.
"MediPurpose certainly did not invent the infant heelstick-a medical device that has been around for several years," said Yi. "However, the market has expressed the need for a neonatal heelstick that better satisfies its end-users' unique requirements. By listening carefully to the end-users, we are confident that our new babyLance will meet their requirements."
About babyLance Infant Heel Incision Devices
Used by neonatal caregivers to collect blood samples from infants, the new babyLance features an ergonomic design to provide a secure and stable grip.
Combined with a redesigned trigger mechanism, the heelstick device is easy to activate, helping to deliver a consistent incision without damaging the baby's tender nerve fibers.
babyLance heelstick devices are available in two models:
* The babyLance BLP (Preemie), which delivers an incision depth of 0.85 mm.
* The babyLance BLN (Newborn), which delivers an incision depth of 1.00 mm.
To download the white papers, please visit http://www.medipurpose.com/downloads.
For more information about babyLance -- including pricing and no-cost product sample requests -- please visit http://www.medipurpose.com/babylance.
About MediPurpose
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance(tm) heel incision device, SurgiLance(tm) safety lancet and MediPlus(tm) advanced wound care products, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and distributors.
MediPurpose's Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose's medical products and solutions for inventors, innovators, manufacturers and distributors, please visit http://www.medipurpose.com.
Contact
MediPurpose
Derek Rudnak
888-808-6494
www.medipurpose.com
Derek Rudnak
888-808-6494
www.medipurpose.com
Contact
Categories